View Item 

Show simple item record

Cyclosporine A
dc.contributor.authorGupta, Aditya K.en_US
dc.contributor.authorEllis, Charles N.en_US
dc.contributor.authorGoldfarb, Michael T.en_US
dc.contributor.authorCooper, Kevin D.en_US
dc.contributor.authorRocher, Leslieen_US
dc.contributor.authorBrown, Marc D.en_US
dc.contributor.authorBaadsgaard, Oleen_US
dc.contributor.authorVoorhees, John J.en_US
dc.date.accessioned2006-04-07T20:46:03Z
dc.date.available2006-04-07T20:46:03Z
dc.date.issued1989en_US
dc.identifier.citationGupta, Aditya K., Ellis, Charles N., Goldfarb, Michael T., Cooper, Kevin D., Rocher, Leslie, Brown, Marc D., Baadsgaard, Ole, Voorhees, John J. (1989)."Cyclosporine A." Clinics in Dermatology 7(3): 98-110. <http://hdl.handle.net/2027.42/27861>en_US
dc.identifier.urihttp://www.sciencedirect.com/science/article/B6T5G-4BP9XXN-4G/2/a4dc51b10bb90a393eebe450e38178c4en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/27861
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=2680025&dopt=citationen_US
dc.description.abstractCyclosporine A (CsA) is a neutral lipophilic compound that was first isolated in the 1970s from the fungal species Tolypocladium inflatum gams. CsA is a cyclic polypeptide that consists of 11 amino acids and that has a molecular weight of 1202 daltons.1 It was found to have potent immunosuppressive properties and was initially used in the late 1970s to prevent organ rejection following transplantation. CsA first became available for general use in North America in 1983 and is now perhaps the most widely used drug to prevent graft rejection in transplantation medicine. The spectrum of conditions for which CsA is now being used has broadened, with recent reports of its benefit in several autoimmune and cutaneous diseases.en_US
dc.format.extent1052293 bytes
dc.format.extent3118 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.language.isoen_US
dc.publisherElsevieren_US
dc.titleCyclosporine Aen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelDermatologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartments of Dermatology and Internal Medicine, University of Michigan Medical Center, Ann Arbor, Michigan, USAen_US
dc.contributor.affiliationumDepartments of Dermatology and Internal Medicine, University of Michigan Medical Center, Ann Arbor, Michigan, USAen_US
dc.contributor.affiliationumDepartments of Dermatology and Internal Medicine, University of Michigan Medical Center, Ann Arbor, Michigan, USAen_US
dc.contributor.affiliationumDepartments of Dermatology and Internal Medicine, University of Michigan Medical Center, Ann Arbor, Michigan, USAen_US
dc.contributor.affiliationumDepartments of Dermatology and Internal Medicine, University of Michigan Medical Center, Ann Arbor, Michigan, USAen_US
dc.contributor.affiliationumDepartments of Dermatology and Internal Medicine, University of Michigan Medical Center, Ann Arbor, Michigan, USAen_US
dc.contributor.affiliationumDepartments of Dermatology and Internal Medicine, University of Michigan Medical Center, Ann Arbor, Michigan, USAen_US
dc.contributor.affiliationumDepartments of Dermatology and Internal Medicine, University of Michigan Medical Center, Ann Arbor, Michigan, USAen_US
dc.identifier.pmid2680025en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/27861/1/0000274.pdfen_US
dc.identifier.doihttp://dx.doi.org/10.1016/0738-081X(89)90011-4en_US
dc.identifier.sourceClinics in Dermatologyen_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
0000274.pdf
Size:
1.003MB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe its collections in a way that respects the people and communities who create, use, and are represented in them. We encourage you to Contact Us anonymously if you encounter harmful or problematic language in catalog records or finding aids. More information about our policies and practices is available at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.